Sotac Pharmaceuticals Ltd
SOTAC NSE
Sotac Pharmaceuticals Ltd
HealthcareNSE: SOTAC Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹99.51 Cr
Volatility
Moderate
P/E Ratio
17.3
EBITDA
₹17.88 Cr
Return on Equity
15.88%
Debt to Equity
0.64
Book Value
₹53.28
52W High
₹139.65
52W Low
₹86
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sotac Pharmaceuticals Ltd insights
29 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 34.7% CAGR over last 5 years
Weaknesses
1- Company has a low return on equity of 13.0% over last 3 years.
Growth Rate
Revenue Growth
0.34% ↘
Net Income Growth
-28.82% ↗
Cash Flow Change
73.07% ↗
ROE
118.73% ↗
ROCE
104.57% ↗
EBITDA Margin (Avg.)
1.27% ↘
Quarterly Results
| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9% | 10% | 9% | 8% | 8% | 26% | 10% | 17% |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| PBT | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49% | 34% | 45% | -34% | 30% | 13% | 23% | 31% |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS in Rs | 6.78 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 29 | 49 | 77 | 104 | 97 | 101 |
| Expenses | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7% | 3% | 10% | 8% | 14% | 18% |
| Other Income | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| PBT | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| Net Profit | 0 | -2 | 2 | 4 | 9 | 6 |
| EPS in Rs | 0.39 | -10.3 | 3.58 | 3.87 | 7.27 | 5.22 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 4% |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 8 | -16 | -4 | 17 |
| Investing | -12 | -3 | -12 | -20 | -14 | -7 |
| Financing | 11 | 3 | 13 | 29 | 16 | -10 |
| Net Cash Flow | 0 | 0 | 10 | -6 | -2 | 0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17 | 8 | 134 | -168 | -26 | 106 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | — | -5% | — | 10% | 15% | 13% |
Documents
1
Bagging/Receiving of orders/contracts
23 Jul - Sotac Pharmaceuticals received Rs. 97.57 lakh order from Intas Pharmaceuticals for formulations, to be supplied by November 5, 2026. 23 Jul - Sotac Pharmaceuticals received Rs. 97.57 lakh order from Intas Pharmaceuticals for formulations, to be supplied by November 5, 2026.
2
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 Jul - Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization or rematerialization received. 9 Jul - Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization or rematerialization received.
3
Outcome of Board Meeting
26 May - Board approved FY26 audited results, recommended Rs 0.20 final dividend, and reported unmodified audit opinion. 26 May - Board approved FY26 audited results, recommended Rs 0.20 final dividend, and reported unmodified audit opinion.
4
Dividend
26 May - Board approved FY26 audited standalone and consolidated results, and recommended Rs.0.20 final dividend per share. 26 May - Board approved FY26 audited standalone and consolidated results, and recommended Rs.0.20 final dividend per share.
5
Structural Digital Database
25 May - Submitted SDD compliance certificate for FY ended March 31, 2026; 9 events captured, no non-compliance. 25 May - Submitted SDD compliance certificate for FY ended March 31, 2026; 9 events captured, no non-compliance.
Frequently Asked Questions about Sotac Pharmaceuticals Ltd
What does Sotac Pharmaceuticals Ltd do?
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
Where is Sotac Pharmaceuticals Ltd (SOTAC) listed?
Sotac Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: SOTAC. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sotac Pharmaceuticals Ltd belong to?
Sotac Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has a market capitalisation of approximately ₹99.51 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Sotac Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Sotac Pharmaceuticals Ltd is 17.30. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sotac Pharmaceuticals Ltd?
Over the past 52 weeks, Sotac Pharmaceuticals Ltd has traded between a low of ₹86 and a high of ₹139.65. This range helps investors understand the stock's price volatility and recent trading levels.
Does Sotac Pharmaceuticals Ltd pay dividends?
Yes, Sotac Pharmaceuticals Ltd has a dividend yield of 0.11%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has a Return on Equity (ROE) of 15.88%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sotac Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Sotac Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products[1]